© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
September 12, 2022
Significant improvements in progression-free survival were seen with sotorasib compared with docetaxel in patients with KRAS G12C–mutated non–small cell lung cancer.
September 11, 2022
Even after additional follow-up, the CLEAR trial showed a benefit for the combination of lenvatinib and pembrolizumab over sunitinib in patients with advanced clear cell renal cell carcinoma.
Positive signals from a blood-based multi-cancer early detection test led to cancer diagnoses after the test indicated potential cancers in 1.4% of individuals from an otherwise healthy cohort of participants in the the prospective PATHFINDER study.
September 10, 2022
The oncolytic virus T-VEC showed consistent improvements at 5 years for patients with stage IIIB to IVM1a melanoma.
A novel tumor-infiltrating lymphocyte therapy showed a 50% reduction in the risk of death for patients with stage IIIC/IV unresectable, treatment-refractory melanoma.
Findings presented at ESMO 2022 show the survival benefits of camrelizumab plus rivoceranib in patients with unresectable HCC.